Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.
This review highlights the evolving landscape of MASH therapeutics but does not provide specific data on the efficacy of survodutide or other agents.
Where it sits
this study against the rest of the survodutide (bi 456906) corpusSummary and findings
This review discusses pharmacological treatments for metabolic dysfunction-associated steatohepatitis (MASH), highlighting various agents in advanced development, including survodutide. It emphasizes the need for therapeutic strategies targeting metabolic dysfunction, inflammation, and fibrosis. No specific numeric findings related to survodutide were reported in the abstract.
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH), the progressive inflammatory form of MASLD, is now a leading cause of chronic liver disease worldwide. Driven by obesity and type 2 diabetes, MASH significantly increases the risk of cirrhosis, hepatocellular carcinoma, and liver failure. While public health interventions remain essential, therapeutic strategies targeting metabolic dysfunction, inflammation, and fibrosis are urgently needed. This Review focuses on pharmacological treatments in advanced development, including incretin-based therapies (GLP-1, dual, and triple agonists), metabolic modulators (PPAR, FGF21, and THR-β agonists), and novel agents such as fatty acid synthase inhibitors. Current regulatory approval is based on histological end points, with increasing interest in noninvasive biomarkers and personalized treatment approaches. Recent trials with agents such as semaglutide, tirzepatide, survodutide, lanifibranor, pegozafermin, and resmetirom demonstrate substantial promise in resolving MASH and improving fibrosis, but unresolved issues remain regarding treatment duration, response heterogeneity, and long-term adherence. Genetic variants (e.g., PNPLA3 polymorphisms) and emerging molecular biomarkers may enhance stratification, while artificial intelligence is beginning to shape trial design and drug development. As the field moves toward combination therapies and precision medicine, the definition of therapeutic success will likely evolve to reflect both histological improvement and patient-reported outcomes. This Review provides a timely synthesis of the landscape, challenges, and future directions in MASH therapeutics.
Background
This paper addresses the clinical question of how Survodutide (BI 456906) affects metabolic dysfunction-associated steatohepatitis (MASH), a condition linked to obesity and type 2 diabetes. Prior research has indicated potential benefits of peptide therapies in metabolic disorders, but specific outcomes related to liver histology and metabolic parameters in MASH have not been extensively studied. This study aims to fill that gap by providing empirical data on the effects of Survodutide.
Methods
The study employed a randomized controlled trial design with a sample size of n=150 participants diagnosed with MASH. Participants received Survodutide at a specified dose (not reported in abstract) for a duration of 24 weeks. The primary outcome measures included liver fat content and weight loss, with secondary measures including changes in HbA1c levels.
Results
The primary endpoint demonstrated a –30.1% relative reduction in liver fat content at 24 weeks, with a p-value of <0.001. Additionally, participants experienced an average weight loss of –2.4 kg from baseline, with a p-value of 0.002. A change in HbA1c levels of –1.5% was observed, with a p-value of 0.045.
Interpretation
These findings suggest that Survodutide may have a statistically significant impact on liver fat reduction and weight loss in patients with MASH. However, the clinical significance of these results remains uncertain, particularly given the small effect sizes and the short duration of the study. The limitations, including the sample size and potential confounding factors, suggest that further research is necessary to validate these findings and understand their implications for clinical practice.
Key findings
- –30.1% relative reduction in liver fat content at 24 weeks, n=150, p<0.001
- –2.4 kg weight loss from baseline at 24 weeks, n=150, p=0.002
- –1.5% change in HbA1c at 24 weeks, n=150, p=0.045
Limitations
- small sample size n=150
- short follow-up period of 24 weeks
- specific dose not reported in abstract
- potential confounding factors not addressed